中国肺癌杂志最新文献

{"title":"[Research Progress on Molecular Mechanisms and Precision Diagnosis \u2029and Treatment of Spinal Organotropic Metastasis in Lung Adenocarcinoma].","authors":"Hongyang Fu, Yitong She, Manglai Li, Yiming Du, Yong Zhu","doi":"10.3779/j.issn.1009-3419.2026.102.19","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.19","url":null,"abstract":"<p><p>Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC), with a high incidence of spinal metastasis and poor prognosis. Spinal metastasis of LUAD is not merely a simple bone metastasis but a directed metastasis process mediated by the anatomical characteristics of the spine, microenvironment specificity, and molecular regulatory mechanisms. However, current research mainly focuses on general bone metastasis, and a dedicated mechanism and precise diagnosis and treatment system for spinal-directed metastasis have not yet been established. Therefore, this article systematically elaborates on the molecular mechanisms of LUAD spinal-directed metastasis from three key aspects: metastatic potential, microenvironment regulation, and metastasis pathways. Combined with the clinical characteristics of spinal metastasis and the current research deficiencies, it provides new ideas for basic research and clinical precise prevention and treatment of LUAD spinal metastasis.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"437-444"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advances in the Growth Risk Assessment and Precision Management \u2029of Pulmonary Subsolid Nodules].","authors":"Shulei Cui, Linlin Qi, Jianwei Wang","doi":"10.3779/j.issn.1009-3419.2026.106.20","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.20","url":null,"abstract":"<p><p>Pulmonary subsolid nodules (SSNs) exhibit heterogeneous growth patterns. Most SSNs remain stable or grow only slowly during long-term follow-up, whereas a small subset grows rapidly over a relatively short period. Some of these lesions may ultimately progress to invasive adenocarcinoma (IAC). Growth is an important imaging manifestation of evolving biological behavior in SSNs. It also serves as a key determinant of surveillance strategies and the timing of intervention. Accordingly, accurate assessment of growth risk has become a major focus of current research. Starting from the natural history of SSNs and the challenges associated with their clinical surveillance and management, this review systematically examines advances in SSNs growth risk assessment across imaging, radiomics, and deep learning. It also summarizes relevant molecular biological evidence to inform accurate growth risk assessment and the development of individualized management strategies for SSNs.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"428-436"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Abnormally Elevated Procalcitonin in Stage IV Lung Adenocarcinoma \u2029with Neuroendocrine Differentiation: A Case Report and Literature Review].","authors":"Yongquan Pan, Ting Wu, Jinfeng Jiang, Tianyu Sun, Chenyang Liu, Hao Ding","doi":"10.3779/j.issn.1009-3419.2026.106.17","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.17","url":null,"abstract":"<p><p>Procalcitonin (PCT) is a key biomarker widely used in clinical practice for the diagnosis of bacterial infection, assessment of antimicrobial efficacy, and prognostic evaluation. Studies have shown that PCT can also be elevated in various malignancies, correlating closely with tumor progression, metastasis, and poor prognosis. However, the value of PCT in monitoring disease status and treatment response in non-small cell lung cancer (NSCLC) remains unclear. This article reports a case of a patient with previously treated stage IV lung adenocarcinoma with neuroendocrine differentiation, who presented with a marked elevation in serum PCT in the absence of active infection. Following local radiotherapy to the pleural metastatic lesion, the PCT level declined rapidly. This report aims to explore the potential clinical significance of PCT in NSCLC with neuroendocrine differentiation and to provide a reference for disease assessment and prognostic evaluation in patients with similar symptoms.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"469-474"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Advances in the Pulmonary Carcinogenic Effects of \u2029Atmospheric Fine Particulate Matter Mediated by GPER].","authors":"Zhenhua Li, Dingbiao Li","doi":"10.3779/j.issn.1009-3419.2026.101.13","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.13","url":null,"abstract":"<p><p>Lung cancer remains the leading cause of cancer-related death worldwide. Fine particulate matter (PM2.5), classified as a group I human carcinogen, has been extensively linked to lung cancer development through epidemiological studies. The G protein-coupled estrogen receptor (GPER) can be activated and induce tumorigenesis by environmental pollutants, and it is significantly overexpressed in lung cancer tissues, highlighting its critical role in disease progression. Research indicates that environmental estrogen-like components and metal ions in PM2.5 can activate GPER, thereby regulating downstream signaling pathways such as mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT). This activation triggers inflammatory responses, oxidative stress, and ferroptosis, ultimately promoting tumor cell proliferation, apoptosis, migration, epithelial-mesenchymal transition, and remodeling of the tumor microenvironment. Collectively, these mechanisms drive the initiation and progression of lung cancer. In summary, GPER serves as a pivotal molecular hub connecting PM2.5 exposure to lung cancer pathogenesis, presenting a promising therapeutic target. Inhibitors targeting GPER may offer novel strategies for the prevention and treatment of lung cancer.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"453-461"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Standardized Construction of Lung Cancer Organoids and Their Application Progress \u2029in the Precise Treatment of Lung Cancer].","authors":"Sen Cao, Wen Li, Xiaokuan Zhang, Tianyi Niu, Zheng Wu, Zhiyu Wang","doi":"10.3779/j.issn.1009-3419.2026.102.20","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.20","url":null,"abstract":"<p><p>Lung cancer is the malignancy with the highest incidence and mortality rates in China. Although significant progress has been made in its treatment due to the application of various novel therapeutic approaches, challenges remain in early diagnosis, as more than half of patients present with distant metastases at diagnosis, indicating a substantial gap compared to ideal precision therapy. Therefore, there is an urgent need to develop a novel personalized diagnostic and therapeutic model. Traditional cancer cell line models lack spatial structure and fail to accurately replicate the growth dynamics of native tissues; patient-derived xenograft models are costly and exhibit low transplantation success rates. In contrast, lung cancer organoids (LCOs) demonstrate superior genetic stability and rapid culture efficiency compared to other models, faithfully simulating the natural growth patterns of primary tumors and reducing animal dependency, making them particularly suitable for large-scale drug screening. However, despite rapid advancements in organoid technology, consensus has yet to be reached regarding standardized LCOs construction methods. This article systematically outlines the standardized development of LCOs models, their applications in precision lung cancer diagnosis and treatment, and recent progress, aiming to guide clinical implementation and improve patients' quality of life and survival outcomes.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"445-452"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[China Wumeng Mountain Lung Cancer: \u2029Evidence Chain, Clinical and Molecular Characteristics of Regional Lung Cancer \u2029Related to Coal Pollution in the Yunnan-Guizhou Plateau].","authors":"","doi":"10.3779/j.issn.1009-3419.2026.102.16","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.16","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Long-term household coal burning, differences in coal sources and mineral compositions, energy structure, and socioeconomic conditions jointly constitute the regional exposure basis for lung cancer. This study conducts a multi-sectional, multi-dimensional and multi-omics investigation on the correlation between coal-burning pollution in the \"Wumeng Mountain region\" and \"China Wumeng Mountain lung cancer\", and explores the concept boundaries, evidence chain, carcinogenic components, clinical and molecular characteristics, as well as the precise prevention and control pathways of \"China Wumeng Mountain lung cancer\", with the aim of providing evidences and references for the primary, secondary, tertiary and quaternary prevention of lung cancer in high-incidence areas of \"China Wumeng Mountain lung cancer\", as well as the screening and molecular typing management of high-risk populations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Based on the relatively complete evidence chain established in our previous research, covering household coal smoke exposure, coal source differences, polycyclic aromatic hydrocarbons (PAHs), stove intervention, lung cancer and tumor multi-omics characteristics, a narrative review method was applied for literature search and evidence integration. The search databases included PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI) and Wanfang Database, with the time range from the establishment of each database to May 2026; search terms included: Xuanwei, Fuyuan, Wumeng Mountains, household coal combustion, smoky coal, lung cancer, PAHs, methylated PAHs, stove improvement, never-smoking women, germline susceptibility, microbiome and multi-omics. The evidence integration adopted the \"exposure-pollutant component-biological effect-clinical molecular characteristics-prevention transformation\" evidence chain.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;(1) PAHs/methylated PAHs, particulate matter 2.5 (PM2.5)/black carbon, inorganic minerals/metals, carbonyl compounds and mixed exposure are the main carcinogenic components of coal-burning pollution-related lung cancer; (2) It is prevalent among non-smoking women, with a high proportion of adenocarcinoma, low age of onset, easy early metastasis, multiple lung lesions and family aggregation are the clinical characteristics of coal-burning pollution-related lung cancer in the Wumeng Mountain region; (3) The total epidermal growth factor receptor (EGFR) mutation is relatively high, but the proportions of classic EGFR 19 exon deletion and L858R mutation are relatively low, while EGFR-G719X, S768I mutations, Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations, and anaplastic lymphoma kinase (ALK) and c-ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene fusion mutations are significantly higher than those in non-Wumeng Mountain lung cancer; (4) Germline mutation genes ARHGEF5, MYO18B and MUC16 are potential genetic susceptibility gen","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"395-411"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Detection Status and Cost Analysis of Community Pulmonary Nodule Screening \u2029with Mobile LDCT Combined with AI].","authors":"Jianjie Wang, Jun Tao, Meilan Zhou, Xiaojun Wang, Gang Wu, Zhengbin Zhang, Zhouqin Lu, Qinghong Lin, Tiantian Wang, Haozhe Zhang, Zhiyi Zheng, Yuehua Li","doi":"10.3779/j.issn.1009-3419.2026.106.15","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.15","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Low-dose computed tomography (LDCT) is the core method for early lung cancer screening, but traditional fixed-institution screening has the problem of insufficient accessibility at the grassroots level. This study aims to evaluate the detection characteristics and influencing factors of pulmonary nodules by mobile LDCT combined with artificial intelligence (AI) in urban communities of Wuhan, and conduct a preliminary cost analysis from the health system perspective, so as to provide scientific basis for optimizing early screening strategies for pulmonary nodules at the primary care level.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A community‑based observational study between August 2024 and May 2025 were conducted. A total of 3436 residents in Wuhan communities completed questionnaire surveys and mobile LDCT scans, with a recruitment response rate of 26.7%. Pulmonary nodules were classified according to the Lung CT Screening Reporting and Data System (Lung-RADS). Multivariate Logistic regression model was used to analyze the independent influencing factors of clinically significant nodules (Lung-RADS category ≥3). Sensitivity analysis was performed by stepwise backward full-variable model, and multicollinearity was tested by variance inflation factor (VIF). Meanwhile, a descriptive cost analysis was conducted in accordance with the CHEERS 2022 statement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The median age of the screened population was 63 years, with 38.7% male and 67.3% aged ≥60 years. The overall detection rate of pulmonary nodules was 84.6%, with clinically significant nodules detected in 10.4% and high-risk nodules in 3.2%. Multivariate Logistic regression analysis showed that age 60-79 years (OR=2.771, 95%CI: 1.004-7.646, P=0.049), age ≥80 years (OR=6.224, 95%CI: 1.813-21.369, P=0.004), heavy smoking (OR=1.919, 95%CI: 1.352-2.724, P&lt;0.001), secondhand smoke exposure (OR=1.762, 95%CI: 1.200-2.586, P=0.004), exposure to harmful chemicals (OR=2.972, 95%CI: 1.881-4.695, P&lt;0.001), long-term kitchen oil fume exposure (OR=1.411, 95%CI: 1.102-1.807, P=0.006), and family history of lung cancer (OR=1.866, 95%CI: 1.173-2.967, P=0.008) were independent risk factors for clinically significant nodules. The total cost of the project was 666,580 CNY, with an average screening cost of 194 CNY per person. Under the whole population strategy, the costs for detecting one clinically significant nodule and one high-risk nodule were 1857 and 6060 CNY, respectively. Screening targeted at individuals aged ≥60 years could cover 87.3% of high-risk nodules, with the cost per high-risk nodule detected reduced to 4676 CNY.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Mobile LDCT combined with AI-assisted screening can effectively identify high-risk individuals of pulmonary nodules in community settings. The elderly and people with multiple exposure risks should be the priority p","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"412-419"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Ileal Perforation Caused by Pleural Mesothelioma-related Small Intestinal Involvement: A Case Report and Literature Review].","authors":"Yunjia Wang, Fangqian Shen, Qisha Li, Xinjuan Li, Hua Yang, Puyu Liu, Xuefeng Yang, Nianjie Zhang, Jianguo Zhou, Yuju Bai","doi":"10.3779/j.issn.1009-3419.2026.106.16","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.16","url":null,"abstract":"<p><p>Pleural mesothelioma (PM) usually manifests as local intrathoracic invasion, and small intestinal involvement is rare. A 37-year-old man with initially diagnosed stage IV diffuse PM and no definite history of asbestos exposure or other specific occupational or environmental exposure except for long-term smoking was reported. After first-line treatment with Pemetrexed, Carboplatin and Bevacizumab, the disease remained stable. However, acute abdomen occurred during maintenance therapy, and emergency surgery confirmed terminal ileal perforation. Postoperative pathology suggested PM-related ileal involvement/metastatic involvement, with a higher Ki-67 proliferation index than that of the primary lesion. Because only perforation repair rather than segmental bowel resection was performed, the available pathological material could not determine whether full-thickness bowel-wall involvement was present or the direction of tumor invasion. Imaging findings, intraoperative findings and pathological results did not support primary peritoneal mesothelioma or direct contiguous invasion of the ileum by the diaphragmatic lesion; however, microscopic peritoneal dissemination with secondary bowel-wall involvement could not be completely excluded. The aim of this report, together with literature review, is to summarize the diagnostic challenges, management strategies and clinical implications of PM-related small intestinal involvement.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"462-468"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert Consensus on Precision Management of Pulmonary Nodules (2026 Version)].","authors":"Juan Zhou, Yudong Zhang, Qinghua Zhou, Chang Chen, Chunxia Su","doi":"10.3779/j.issn.1009-3419.2026.102.08","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.08","url":null,"abstract":"<p><p>With the wide application of low-dose spiral computed tomography and the advancement of imaging technology, the detection rate of pulmonary nodules has significantly increased. However, the traditional \"one-size-fits-all\" management strategy has been unable to meet the needs of precise diagnosis and treatment. This expert consensus was initiated by Professor Chunxia SU's team and Professor Chang CHEN's team from Shanghai Pulmonary Hospital and jointly formulated by experts from multiple disciplines including oncology, respiratory medicine, thoracic surgery, interventional medicine, radiology, and pathology. The aim is to provide scientific and practical decision-making references for clinical controversies that are less addressed or have differences in existing guidelines. The consensus uses the GRADE method for evidence assessment and forms 18 recommendations through two rounds of Delphi questionnaire surveys, focusing on differentiated screening for special populations, artificial intelligence assisted diagnosis, robot-assisted puncture, application of molecular markers, active monitoring of low-risk nodules, timing of invasive intervention, termination conditions of follow-up, management strategies for multiple nodules, and selection of individualized lymph node dissection range and surgical methods for early-stage lung cancer. This consensus would provides supplementary guidance for the entire process of precise management of pulmonary nodules from screening to treatment, with expectation of improving the long-term survival rate of lung cancer patients while minimizing unnecessary medical interventions and enhancing the quality of life of patients.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 5","pages":"315-331"},"PeriodicalIF":0.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese Expert Consensus on Diagnosis and Treatment of Non-small Cell Lung Cancer with MET Abnormality (2026 Version)].","authors":"Jun Chen, Baohui Han, Yi Hu, Jian Hu, Yuankai Shi","doi":"10.3779/j.issn.1009-3419.2026.102.13","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.13","url":null,"abstract":"<p><p>The mesenchymal-epithelial transition factor (MET) gene, located on human chromosome 7, exerts critical regulatory roles in cellular processes including proliferation, migration, invasion, and angiogenesis. As a key driver gene in non-small cell lung cancer (NSCLC), MET abnormalities encompass MET exon 14 (METex14) skipping mutations, gene amplification, protein overexpression, gene fusions, and activating mutations. This consensus, developed by the Lung Cancer Specialty Committee of the Chinese Elderly Health Care Association, updates the 2025 version with several key modifications: elevating the recommendation level for MET amplification and protein overexpression testing, advocating routine testing for all newly diagnosed NSCLC patients and those with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs); standardizing targeted therapy approaches for MET amplification in driver gene-negative settings and following EGFR-TKIs resistance; and subdividing MET protein overexpression-related management into post-EGFR-TKIs resistance and driver gene-negative categories with corresponding treatment protocols, thereby offering more actionable guidance for precise clinical decision-making.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 5","pages":"332-347"},"PeriodicalIF":0.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}